Pfizer’s decision to make their HDL-raising drug only in combination with Lipitor is coming under fire

Pfizer’s decision to make their HDL-raising drug only in combination with Lipitor is coming under fire

Previously written about in the NY Times, this reeks of protecting Lipitor profits after its patent runs out. There are many who would benefit from torcetrapib that cannot take Lipitor for one reason or another. Give patients a choice.